Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 48.02% | -29.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.07% | -20.31% | |||
| Operating Income | -5.07% | 20.31% | |||
| Income Before Tax | -26.74% | 60.65% | |||
| Income Tax Expenses | -1,133.33% | 100.00% | |||
| Earnings from Continuing Operations | -21.13% | 60.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.13% | 60.50% | |||
| EBIT | -5.07% | 20.31% | |||
| EBITDA | -5.31% | 20.45% | |||
| EPS Basic | -21.37% | 75.20% | |||
| Normalized Basic EPS | 19.26% | 60.50% | |||
| EPS Diluted | -21.37% | 75.20% | |||
| Normalized Diluted EPS | 19.26% | 60.50% | |||
| Average Basic Shares Outstanding | 0.38% | 58.83% | |||
| Average Diluted Shares Outstanding | 0.38% | 58.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||